India's Richest People 2026 edition · 1 director · Source: Hurun India
- #893 Jayesh P Choksi & family ₹3,300 Cr
Market Cap
₹4,249 Cr
GUFICBIO · NSE
Share Price
₹418.80
-1.17% today
Revenue
₹944 Cr
FY 2025-26 · +15.2% YoY
EBITDA
₹151 Cr
Margin 16.0%
Net Profit
₹64.22 Cr
FY 2025-26 · -7.6% YoY
P/E (TTM)
57.4x
P/B 6.3x
ROE
10.1%
ROCE 12.0%
Debt / Equity
0.59
Interest cover 30.4x
About Gufic Biosciences Limited
Data last updated:
Gufic Biosciences Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 23 July 1984 and has been in existence for over 42 years.
Its director Jayesh P Choksi and family are #893 among India's richest people (2026).
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L24100MH1984PLC033519. Its GSTIN is 27AAACC3419N1ZK (Maharashtra). The company holds 22 GST registrations, of which 20 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 509079 and NSE: GUFICBIO.
The company has an authorised share capital of ₹85.75 Cr and a paid-up capital of ₹10.03 Cr. It was formerly known as Central Leasing Limited. It is led by directors including Jayesh Pannalal Choksi (Managing Director) and Pranav Jayesh Choksi (Whole-Time Director).
Its last annual general meeting (AGM) was held on 29 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Shop – 37 First Floor Kamala Bhavan II S Nityanand Road Andheri East, Mumbai, Maharashtra, India – 400069.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹944.01 Cr, a growth of 15.1% compared to the previous year. For the same year it recorded a net profit of ₹64.22 Cr (net margin 6.8%) and EBITDA of ₹151.33 Cr (EBITDA margin 16%). The net worth stands at ₹664.95 Cr (up 10.6% YoY). Total assets are valued at ₹1,093.3 Cr (up 13.9% YoY).
The company has about 1,362 employees on its provident fund (EPFO) records. Its group structure includes 1 subsidiary.
The company is associated with 1 brand: Gufic Group. As per MCA filings, the company has open charges of ₹604.73 Cr and satisfied charges of ₹201.91 Cr on record. Court records list 254 cases involving the company, including 204 filed by the company and 50 filed against it; 120 cases are pending. The company has 18 deals on record (17 market trades, 1 funding round), with disclosed funding of ₹99.99 Cr; the latest was in November 2023. Its 8 peer companies in the Pharma industry (Biosciences, Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 5 larger and 3 smaller; the largest is Rubicon Research Limited with revenue of ₹872.39 Cr. The company has 14 MSME Form 1 returns on record between 2019 and 2024, listing 2,784 overdue payments to 28 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website gufic.com.
Company details
CIN L24100MH1984PLC033519
Registration Number 033519
Incorporation Date 23 July 1984
ROC Mumbai
Listing Status Listed - Listed on NSE (GUFICBIO); Listed on BSE (509079)
Company Status Active
Date of Last AGM 29 September 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
CIN history
Gufic Biosciences has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24100MH1984PLC033519, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24100MH1984PLC033519 | Current |
| L65990MH1901PLC033519 | Previous |
| L65990MH1984PLC033519 | Previous |
Key People
Jayesh Pannalal Choksi Managing Director Pranav Jayesh Choksi Whole-Time Director Pankaj Jayakumar Gandhi Whole-Time Director Recognitions & Rankings of Gufic Biosciences
Contact details
Gufic Biosciences Limited's registered office is in Mumbai, Maharashtra. Its website is gufic.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered AddressShop – 37 First Floor Kamala Bhavan II S Nityanand Road Andheri East, Mumbai, Maharashtra, India – 400069
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Gufic Biosciences Limited, buy the company report.
Comprehensive company report
Gufic Biosciences Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Gufic Biosciences operates one associated brand: Gufic Group. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Lyophilized injections and pharmaceutical products are manufactured across therapeutic segments. | gufic.com |
Business activity
The main business activity of Gufic Biosciences is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Gufic Biosciences Limited, buy the company report.
Financials of Gufic Biosciences Limited
FY 2025-26 filings availableGufic Biosciences Limited reported revenue of ₹944.01 Cr (up 15.1% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue
₹944 Cr
+15.1% YoY
EBITDA
₹151 Cr
+11.2% YoY
Profit After Tax
₹64.22 Cr
-7.6% YoY
Net Worth
₹665 Cr
+10.6% YoY
Total Assets
₹1,093 Cr
+13.9% YoY
Total Debt
₹405 Cr
+20.4% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Income statement | |||
| Revenue | 944 | 820 | 807 |
| Revenue growth | +15.2% | +1.6% | - |
| EBITDA | 151 | 136 | 147 |
| EBITDA margin | +16.0% | +16.6% | +18.3% |
| Profit before tax | 86.55 | 94.13 | 116 |
| Net profit | 64.22 | 69.49 | 87.81 |
| Net profit margin | +6.8% | +8.5% | +10.9% |
| EPS (₹) | 6.40 | 6.95 | 8.59 |
| Balance sheet | |||
| Total assets | 1,093 | 960 | 886 |
| Net worth | 665 | 601 | 533 |
| Total debt | 405 | 336 | 333 |
| Cash & bank | 76.22 | 29.02 | 13.48 |
| Net working capital | 570 | 423 | 396 |
| Cash flow | |||
| Cash from operations | 45.14 | 123 | (7.46) |
| Cash from investing | (30.96) | (70.78) | (102) |
| Cash from financing | 32.29 | (37.20) | 82.38 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 261 | 252 | 231 | 237 | 224 | 205 | 208 | 204 |
| Revenue growth (YoY) | +16.6% | +22.8% | +11.4% | +16.1% | +10.3% | - | - | - |
| Other income | 0.46 | (1.17) | 0.79 | 2.12 | 0.93 | 0.39 | 1.86 | 0.11 |
| EBITDA | 46.61 | 47.21 | 32.98 | 37.84 | 33.30 | 26.37 | 33.92 | 38.62 |
| EBITDA margin | +17.9% | +18.7% | +14.3% | +16.0% | +14.9% | +12.9% | +16.3% | +18.9% |
| Depreciation | 7.71 | 7.65 | 7.69 | 7.77 | 7.72 | 7.84 | 4.62 | 4.30 |
| Interest | 9.32 | 9.44 | 8.36 | 9.58 | 9.23 | 8.40 | 4.91 | 5.18 |
| Profit before tax | 30.04 | 28.95 | 17.72 | 22.61 | 17.28 | 10.52 | 26.25 | 29.25 |
| Tax | 7.73 | 7.05 | 5.30 | 5.78 | 4.20 | 2.80 | 6.96 | 7.49 |
| Net profit | 22.31 | 21.90 | 12.42 | 16.83 | 13.08 | 7.72 | 19.29 | 21.76 |
| EPS (₹) | 2.22 | 2.18 | 1.24 | 1.68 | 1.30 | 0.77 | 1.93 | 2.17 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 940 | 820 | 807 | 691 | 779 | 488 | 379 |
| Revenue growth | +14.7% | +1.6% | +16.8% | -11.4% | +59.8% | +28.7% | - |
| EBITDA | 150 | 136 | 147 | 135 | 148 | 83.92 | 52.12 |
| EBITDA margin | +16.0% | +16.6% | +18.3% | +19.5% | +19.0% | +17.2% | +13.8% |
| Profit before tax | 85.49 | 94.42 | 116 | 107 | 127 | 57.71 | 30.14 |
| Net profit | 63.16 | 69.78 | 87.81 | 79.68 | 95.79 | 44.21 | 22.69 |
| Net profit margin | +6.7% | +8.5% | +10.9% | +11.5% | +12.3% | +9.1% | +6.0% |
| EPS (₹) | 6.30 | 6.97 | 8.59 | 8.22 | 9.89 | 4.56 | 2.34 |
| Balance sheet | |||||||
| Total assets | 1,092 | 960 | 886 | 700 | 351 | 250 | 268 |
| Net worth | 664 | 601 | 533 | 348 | 269 | 173 | 129 |
| Total debt | 405 | 336 | 333 | 334 | 64.39 | 61.54 | 126 |
| Cash & bank | 74.36 | 28.21 | 13.47 | 46.69 | 26.57 | 13.18 | 16.37 |
| Net working capital | 568 | 422 | 396 | 303 | 150 | 120 | 134 |
| Cash flow | |||||||
| Cash from operations | 44.19 | 123 | (7.46) | (26.59) | 106 | 87.25 | 47.10 |
| Cash from investing | (30.96) | (71.79) | (102) | (191) | (94.59) | (6.69) | (42.53) |
| Cash from financing | 32.19 | (37.20) | 82.38 | 234 | (6.24) | (78.62) | (4.21) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 261 | 252 | 231 | 230 | 227 | 205 | 208 | 204 |
| Revenue growth (YoY) | +14.9% | +22.9% | +11.2% | +12.9% | +11.9% | - | - | - |
| Other income | 0.46 | (1.20) | 0.79 | 2.09 | 0.89 | 0.38 | 1.86 | 0.11 |
| Total expenses | 214 | 206 | 195 | 195 | 195 | 178 | 174 | 166 |
| EBITDA | 46.73 | 45.91 | 36.30 | 35.80 | 32.33 | 26.64 | 33.94 | 38.62 |
| EBITDA margin | +17.9% | +18.2% | +15.7% | +15.5% | +14.2% | +13.0% | +16.3% | +18.9% |
| Depreciation | 7.71 | 7.65 | 7.69 | 7.77 | 7.72 | 7.84 | 4.62 | 4.30 |
| Interest | 9.32 | 9.44 | 8.36 | 9.58 | 9.23 | 8.40 | 4.91 | 5.18 |
| Profit before tax | 30.16 | 27.62 | 21.04 | 20.54 | 16.27 | 10.78 | 26.27 | 29.25 |
| Tax | 7.70 | 7.05 | 5.49 | 5.59 | 4.20 | 2.80 | 6.96 | 7.49 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 29 Oct 2026
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 261 | 252 | 231 | 237 | 224 | 205 | 208 | 204 |
| Revenue growth (YoY) | +16.6% | +22.8% | +11.4% | +16.1% | +10.3% | - | - | - |
| Other income | 0.46 | (1.17) | 0.79 | 2.12 | 0.93 | 0.39 | 1.86 | 0.11 |
| EBITDA | 46.61 | 47.21 | 32.98 | 37.84 | 33.30 | 26.37 | 33.92 | 38.62 |
| EBITDA margin | +17.9% | +18.7% | +14.3% | +16.0% | +14.9% | +12.9% | +16.3% | +18.9% |
| Depreciation | 7.71 | 7.65 | 7.69 | 7.77 | 7.72 | 7.84 | 4.62 | 4.30 |
| Interest | 9.32 | 9.44 | 8.36 | 9.58 | 9.23 | 8.40 | 4.91 | 5.18 |
| Profit before tax | 30.04 | 28.95 | 17.72 | 22.61 | 17.28 | 10.52 | 26.25 | 29.25 |
| Tax | 7.73 | 7.05 | 5.30 | 5.78 | 4.20 | 2.80 | 6.96 | 7.49 |
| Net profit | 22.31 | 21.90 | 12.42 | 16.83 | 13.08 | 7.72 | 19.29 | 21.76 |
| EPS (₹) | 2.22 | 2.18 | 1.24 | 1.68 | 1.30 | 0.77 | 1.93 | 2.17 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Revenue | 944 | 820 | 807 |
| Revenue growth | +15.2% | +1.6% | - |
| Other income | 2.66 | 3.63 | 2.18 |
| Total expenses | 793 | 684 | 659 |
| Employee cost | 152 | 127 | 110 |
| EBITDA | 151 | 136 | 147 |
| EBITDA margin | +16.0% | +16.6% | +18.3% |
| Depreciation | 30.83 | 21.06 | 17.02 |
| Interest | 36.61 | 24.52 | 16.79 |
| Profit before tax | 86.55 | 94.13 | 116 |
| Tax | 22.33 | 24.49 | 29.54 |
| Net profit | 64.22 | 69.49 | 87.81 |
| Net profit margin | +6.8% | +8.5% | +10.9% |
| EPS (₹) | 6.40 | 6.95 | 8.59 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Equity & liabilities | |||
| Share capital | 10.03 | 10.03 | 10.03 |
| Reserves & surplus | 655 | 591 | 523 |
| Shareholders' funds (net worth) | 665 | 601 | 533 |
| Minority interest | 0.04 | 0.00 | 0.00 |
| Secured loans | 385 | 310 | 317 |
| Unsecured loans | 19.59 | 25.82 | 15.88 |
| Total debt | 405 | 336 | 333 |
| Total liabilities | 1,093 | 960 | 886 |
| Assets | |||
| Gross block | 630 | 614 | 246 |
| Net block | 491 | 506 | 159 |
| Capital work in progress | 22.14 | 21.82 | 307 |
| Investments | 1.78 | 1.78 | 1.78 |
| Inventories | 324 | 217 | 200 |
| Sundry debtors | 297 | 315 | 330 |
| Cash & bank balances | 76.22 | 29.02 | 13.48 |
| Loans & advances | 104 | 64.02 | 56.58 |
| Total current assets | 802 | 625 | 600 |
| Total current liabilities | 233 | 201 | 205 |
| Net working capital | 570 | 423 | 396 |
| Total assets | 1,093 | 960 | 886 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Opening cash | 15.72 | 1.14 | 28.60 |
| Net cash from operating activities | 45.14 | 123 | (7.46) |
| Net cash from investing activities | (30.96) | (70.78) | (102) |
| Net cash from financing activities | 32.29 | (37.20) | 82.38 |
| Net change in cash | 46.46 | 14.59 | (27.47) |
| Closing cash | 76.22 | 29.02 | 13.48 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 |
|---|---|---|---|
| Growth | |||
| Sales growth | +15.2% | +1.6% | - |
| EBITDA growth | +11.2% | -7.6% | - |
| PBT growth | -8.1% | -18.6% | +9997.0% |
| Net income growth | -7.6% | -20.9% | - |
| Profitability & leverage | |||
| Net income margin | +6.8% | +8.5% | +10.7% |
| Return on capital employed | +12.0% | +12.9% | +15.0% |
| Return on net worth | +10.1% | +12.3% | +16.2% |
| Debt / equity | 0.59 | 0.59 | 0.63 |
| Long-term debt / equity | 0.21 | 0.28 | 0.31 |
| Interest cover | 30.38 | 21.32 | 12.89 |
| Efficiency & per share | |||
| Fixed asset turnover | 1.52 | 1.91 | 3.28 |
| Inventory turnover | 3.49 | 3.93 | 4.02 |
| Debtors turnover | 3.08 | 2.54 | 2.44 |
| EPS (₹) | 6.40 | 6.95 | 8.59 |
| Dividend per share (₹) | 0.10 | 0.10 | 0.10 |
| Book value per share (₹) | 66.31 | 59.93 | 53.11 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 261 | 252 | 231 | 230 | 227 | 205 | 208 | 204 |
| Revenue growth (YoY) | +14.9% | +22.9% | +11.2% | +12.9% | +11.9% | - | - | - |
| Other income | 0.46 | (1.20) | 0.79 | 2.09 | 0.89 | 0.38 | 1.86 | 0.11 |
| Total expenses | 214 | 206 | 195 | 195 | 195 | 178 | 174 | 166 |
| EBITDA | 46.73 | 45.91 | 36.30 | 35.80 | 32.33 | 26.64 | 33.94 | 38.62 |
| EBITDA margin | +17.9% | +18.2% | +15.7% | +15.5% | +14.2% | +13.0% | +16.3% | +18.9% |
| Depreciation | 7.71 | 7.65 | 7.69 | 7.77 | 7.72 | 7.84 | 4.62 | 4.30 |
| Interest | 9.32 | 9.44 | 8.36 | 9.58 | 9.23 | 8.40 | 4.91 | 5.18 |
| Profit before tax | 30.16 | 27.62 | 21.04 | 20.54 | 16.27 | 10.78 | 26.27 | 29.25 |
| Tax | 7.70 | 7.05 | 5.49 | 5.59 | 4.20 | 2.80 | 6.96 | 7.49 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 940 | 820 | 807 | 691 | 779 | 488 | 379 |
| Revenue growth | +14.7% | +1.6% | +16.8% | -11.4% | +59.8% | +28.7% | - |
| Other income | 2.58 | 3.62 | 2.18 | 2.57 | 3.10 | 3.73 | 5.79 |
| Total expenses | 790 | 683 | 659 | 556 | 631 | 404 | 327 |
| Employee cost | 152 | 127 | 110 | 86.73 | 85.61 | 66.22 | 58.59 |
| EBITDA | 150 | 136 | 147 | 135 | 148 | 83.92 | 52.12 |
| EBITDA margin | +16.0% | +16.6% | +18.3% | +19.5% | +19.0% | +17.2% | +13.8% |
| Depreciation | 30.83 | 21.06 | 17.02 | 22.28 | 18.93 | 16.31 | 13.86 |
| Interest | 36.61 | 24.52 | 16.79 | 8.22 | 5.37 | 13.63 | 13.91 |
| Profit before tax | 85.49 | 94.42 | 116 | 107 | 127 | 57.71 | 30.14 |
| Tax | 22.33 | 24.49 | 29.54 | 27.02 | 31.00 | 13.48 | 7.44 |
| Net profit | 63.16 | 69.78 | 87.81 | 79.68 | 95.79 | 44.21 | 22.69 |
| Net profit margin | +6.7% | +8.5% | +10.9% | +11.5% | +12.3% | +9.1% | +6.0% |
| EPS (₹) | 6.30 | 6.97 | 8.59 | 8.22 | 9.89 | 4.56 | 2.34 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 10.03 | 10.03 | 10.03 | 9.69 | 9.69 | 9.69 | 9.69 |
| Reserves & surplus | 654 | 591 | 523 | 338 | 259 | 164 | 120 |
| Shareholders' funds (net worth) | 664 | 601 | 533 | 348 | 269 | 173 | 129 |
| Secured loans | 385 | 310 | 317 | 311 | 61.24 | 55.35 | 117 |
| Unsecured loans | 19.59 | 25.82 | 15.88 | 22.79 | 3.15 | 6.19 | 9.66 |
| Total debt | 405 | 336 | 333 | 334 | 64.39 | 61.54 | 126 |
| Total liabilities | 1,092 | 960 | 886 | 700 | 351 | 250 | 268 |
| Assets | |||||||
| Gross block | 630 | 614 | 246 | 229 | 180 | 149 | 115 |
| Net block | 491 | 506 | 159 | 160 | 115 | 99.97 | 82.58 |
| Capital work in progress | 22.14 | 21.82 | 307 | 170 | 40.87 | 13.40 | 30.61 |
| Investments | 2.87 | 2.81 | 1.79 | 0.78 | 0.01 | 0.01 | 0.01 |
| Inventories | 324 | 217 | 200 | 183 | 116 | 94.40 | 122 |
| Sundry debtors | 297 | 315 | 330 | 205 | 152 | 124 | 107 |
| Cash & bank balances | 74.36 | 28.21 | 13.47 | 46.69 | 26.57 | 13.18 | 16.37 |
| Loans & advances | 104 | 64.09 | 56.58 | 28.50 | 27.06 | 28.50 | 27.50 |
| Total current assets | 800 | 624 | 600 | 464 | 321 | 261 | 273 |
| Total current liabilities | 233 | 201 | 205 | 161 | 170 | 140 | 139 |
| Net working capital | 568 | 422 | 396 | 303 | 150 | 120 | 134 |
| Total assets | 1,092 | 960 | 886 | 700 | 351 | 250 | 268 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 14.91 | 1.13 | 28.60 | 11.61 | 6.20 | 4.26 | 3.90 |
| Net cash from operating activities | 44.19 | 123 | (7.46) | (26.59) | 106 | 87.25 | 47.10 |
| Net cash from investing activities | (30.96) | (71.79) | (102) | (191) | (94.59) | (6.69) | (42.53) |
| Net cash from financing activities | 32.19 | (37.20) | 82.38 | 234 | (6.24) | (78.62) | (4.21) |
| Net change in cash | 45.42 | 13.78 | (27.48) | 16.99 | 5.41 | 1.94 | 0.36 |
| Closing cash | 74.36 | 28.21 | 13.47 | 46.69 | 26.57 | 13.18 | 16.37 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +14.7% | +1.6% | +16.8% | -11.4% | +59.8% | +28.7% | - |
| EBITDA growth | +10.2% | -7.4% | +9.4% | -9.0% | +76.4% | +61.0% | - |
| PBT growth | -9.5% | -18.4% | +8.4% | -15.9% | +119.8% | +91.5% | -14.7% |
| Net income growth | -9.5% | -20.5% | +10.2% | -16.8% | +116.7% | +94.8% | - |
| Revenue CAGR (3Y) | +10.8% | +1.7% | +18.3% | +22.2% | +30.5% | +16.9% | +15.6% |
| EBITDA CAGR (3Y) | +3.7% | -2.7% | +20.6% | +37.2% | +47.7% | +29.4% | +31.4% |
| Profitability & leverage | |||||||
| Net income margin | +6.7% | +8.5% | +10.7% | +11.5% | +12.3% | +9.1% | +6.0% |
| Return on capital employed | +11.9% | +12.9% | +16.7% | +21.9% | +44.0% | +27.5% | +19.7% |
| Return on net worth | +10.0% | +12.3% | +19.6% | +25.8% | +43.3% | +29.2% | +22.2% |
| Debt / equity | 0.59 | 0.59 | 0.76 | 0.65 | 0.28 | 0.62 | 1.10 |
| Long-term debt / equity | 0.21 | 0.28 | 0.42 | 0.41 | 0.20 | 0.21 | 0.18 |
| Interest cover | 30.63 | 21.26 | 12.89 | 7.32 | 4.16 | 20.16 | 36.36 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 1.51 | 1.91 | 3.40 | 3.38 | 4.75 | 3.70 | 4.98 |
| Inventory turnover | 3.47 | 3.93 | 4.20 | 4.62 | 7.42 | 4.50 | 3.50 |
| Debtors turnover | 3.07 | 2.54 | 3.01 | 3.87 | 5.65 | 4.21 | 3.61 |
| EPS (₹) | 6.30 | 6.97 | 8.59 | 8.22 | 9.89 | 4.56 | 2.34 |
| Dividend per share (₹) | 0.10 | 0.10 | 0.10 | 0.10 | 0.10 | 0.10 | 0.05 |
| Book value per share (₹) | 66.23 | 59.96 | 53.11 | 35.88 | 27.76 | 17.89 | 13.34 |
To see the full year-wise statements and ratios of Gufic Biosciences Limited, buy the company report.
Board of directors of Gufic Biosciences Limited
Gufic Biosciences has 6 current directors and 17 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Pranav Jayesh Choksi | Whole-Time Director | 25 Jun 2004 | 22 Years 4 Months | Current |
| Anu Sanjiv Aurora | Director | 23 Dec 2019 | 6 Years 10 Months | Current |
| Pankaj Jayakumar Gandhi | Whole-Time Director | 01 Aug 2013 | 13 Years 2 Months | Current |
| Jayesh Pannalal Choksi | Managing Director | 31 Aug 1999 | 27 Years 1 Months | Current |
| Akshya Kumar Mahapatra | Director | 14 Nov 2024 | 1 Years 11 Months | Current |
| Kamal Kishore Seth | Director | 27 Jun 2024 | 2 Years 4 Months | Current |
Peer comparison
Gufic Biosciences Limited is compared with the 8 companies closest to it by revenue in the Pharma industry (Biosciences, Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Gufic Biosciences Limitedthis company | ₹944.01 Cr (FY 2026) | ₹64.22 Cr | 6.8% | 15.1% | 1,362 | Mumbai, Maharashtra, India |
| Rubicon Research Limited | ₹872.39 Cr (FY 2024) | 108.0% | Thane, Maharashtra, India | |||
| Fresenius Kabi Oncology Limited | ₹848.26 Cr (FY 2025) | 4.0% | New Delhi, Delhi, India | |||
| Scott Edil Pharmacia Limited | ₹847.96 Cr (FY 2025) | 7.0% | Chandigarh, India | |||
| Bliss GVS Pharma Limited | ₹846.22 Cr (FY 2025) | 6.0% | Mumbai, Maharashtra, India | |||
| Apex Laboratories Private Limited | ₹834.88 Cr (FY 2025) | 7.0% | Chennai, Tamil Nadu, India | |||
| Synokem Pharmaceuticals Limited | ₹791.15 Cr (FY 2025) | 0.0% | New Delhi, Delhi, India | |||
| Prime Pharmaceuticals Private Limited | ₹783.06 Cr (FY 2025) | 131.0% | Mumbai, Maharashtra, India | |||
| Windlas Biotech Limited | ₹777.9 Cr (FY 2025) | 21.0% | Dehradun, Uttarakhand, India |
To see the full peer comparison of Gufic Biosciences Limited, buy the company report.
Auditor
Gufic Biosciences Limited is audited by MITTAL AGARWAL & COMPANY for the financial year 2025.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| MITTAL AGARWAL & COMPANY | FY 2025 | 131025W |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 72.50%, foreign institutional investors hold 0.50%, domestic institutional investors hold 3.60% and retail and other public shareholders hold 23.40%.
Sep 2026
QUARTER
72.50% Promoters
3.60% DII (Domestic Institutional)
0.50% FII (Foreign Institutional)
23.40% Retail & Others
Promoter holding - history
Now 72.50% · Sep 2026High 72.50% · Dec 2025Low 72.50% · Dec 2025
Shareholding trend - last 6 quarters
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 72.50% | 72.50% | 72.50% | 72.50% |
| Public | 27.50% | 27.50% | 27.50% | 27.50% |
Charges & borrowings
Open charges
₹604.73 Cr
Satisfied charges
₹201.91 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 26 Sep 2025 | 101170931 | Others | ₹15.3 Lakh | Open | |
| 31 Jan 2025 | 101051744 | Others | ₹29.5 Lakh | Open | |
| 31 Jan 2025 | 101051749 | Others | ₹29.5 Lakh | Open | |
| 18 Jun 2024 | 100943872 | Others | ₹80 Cr | Open | |
| 31 May 2024 | 100936026 | Others | ₹10 Lakh | Open |
To see the full charge records of Gufic Biosciences Limited, buy the company report.
Total charge records: 54 View all charges
Deals & funding
Gufic Biosciences Limited has 18 deals on record (17 market trades, 1 funding round), with disclosed funding of ₹99.99 Cr; the latest was in November 2023.
Total deals
18
Market trades
17
Funding round
1
Disclosed funding
₹99.99 Cr
Deals on record (5 of 18)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Nov 2023 | Market trade | ₹19.38 Cr | Buyer: Graviton Research Capital LLP Seller: Graviton Research Capital LLP |
| Oct 2023 | Funding round | ₹99.99 Cr | Investors: Motilal Oswal Securities Limited |
| May 2021 | Market trade | ₹8.75 Cr | Buyer: Graviton Research Capital LLP Seller: Graviton Research Capital LLP |
| May 2017 | Market trade | ₹97.89 Cr | Buyer: Sbi Mutual Fund, Parth Infin Brokers Private Limited , Gkn Securities Seller: Sambhav Properties LLP , Parth Infin Brokers Private Limited , Gkn Securities |
| May 2017 | Market trade | ₹8.69 Cr | Buyer: Parth Infin Brokers Private Limited , Gkn Securities Seller: Parth Infin Brokers Private Limited , Gkn Securities |
To see the full deal history of Gufic Biosciences Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Gufic Biosciences Limited has 254 court cases on record: 204 filed by Gufic Biosciences, 50 filed against it. 120 cases are pending and 134 are disposed.
Total cases
254
Filed by the company
204
Filed against the company
50
Pending
120
Disposed
134
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 207 | 35 | 104 |
| High courts | 47 | 15 | 16 |
Cases on record (5 of 254)
| Court | Type of case | Party | Status |
|---|---|---|---|
| High Court of Delhi | Court case (C.O. (COMM.IPD-TM)) | Filed against the company by Apex Laboratories Pvt Ltd | Pending |
| District court, New Delhi, Delhi | Court case (CS (COMM.)) | Filed by the company against Sahajanand Life Sciences Pvt. Ltd. | Pending |
| District court, Mumbai CMM Courts, Maharashtra | Court case (Summary case) | Filed by the company against M/S Suncure Lifescience Private Limited | Pending |
| District court, Mumbai CMM Courts, Maharashtra | Court case (Summary Case) | Filed by the company against M S Jade Life Sciences Private Ltd (Private Limited Company) and 2 others | Pending |
| High Court of Delhi | Court case (C.O. (COMM.IPD-TM)) | Filed by the company against Neon Laboratories Limited & Anr. | Pending |
To see the full case history of Gufic Biosciences Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Gufic Biosciences Limited has 14 MSME Form 1 returns on record between 2019 and 2024, listing 2,784 overdue payments to 28 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 28)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Pretox Research Centre | |||
| Abhinav Healthcare Products Private Limited | |||
| Venus Print N Pack | |||
| Nipa Offset Printers | |||
| Daman Research and Testing Center |
To see the full MSME payment records of Gufic Biosciences Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Group structure & subsidiaries
Gufic Biosciences has 1 subsidiary company. This group structure data is as of FY 2025. The table lists each entity with its relationship and holding.
1
Subsidiary companies
Key subsidiaries
| Company Name | CIN | Shares held |
|---|---|---|
| Gufic Prime Private Limited | U46497MP2023PTC068618 |
To see the full group structure of Gufic Biosciences Limited, buy the company report.
Employees & EPFO
Gufic Biosciences Limited has a workforce of 1,362 employees on its EPFO records as of Sep 23, 2025, across 2 active EPFO establishments.
Employee count
1,362
Active EPFO establishments
2
Employee growth
-11.04%
GST
Gufic Biosciences has 22 GST registrations: 20 active and 2 cancelled or inactive. The first 4 active GSTINs are listed below.
Total GSTINs
22
Active
20
Cancelled / inactive
2
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAACC3419N1ZK | Maharashtra | Active | 01 Jul 2017 |
| 27AAACC3419N2ZJ | Maharashtra | Active | 28 Sep 2019 |
| 07AAACC3419N1ZM | Delhi | Active | 01 Jul 2017 |
| 08AAACC3419N1ZK | Rajasthan | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Gufic Biosciences Limited, buy the company report.
Recent activity
Gufic Biosciences Limited has 34 board changes on record since 1999: 20 appointments and 14 cessations. The latest: Gopal Madhavbhai Daptari ceased to be Director on 24 Nov 2024.
Charges
A charge registered on 14 Feb 2022 via Charge ID 100545057 with Others was fully satisfied on 24 Jun 2026.
Filing
Gufic Biosciences Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Mumbai I.
AGM
Gufic Biosciences Limited last Annual general meeting of members was held on 29 Sep 2025 as per latest MCA records.
Charges
A charge with Others amounted to Rs. 0.15 Cr with Charge ID 101170931 was registered on 26 Sep 2025.
Charges
A charge with Others of Rs. 80.00 Cr registered on 18 Jun 2024 with Charge ID 100943872 was modified on 22 Sep 2025.
Charges
A charge with Hdfc Bank Limited of Rs. 205.00 Cr registered on 08 Dec 2022 with Charge ID 100670629 was modified on 19 Sep 2025.
Charges
A charge with Others of Rs. 33.00 Cr registered on 04 Jan 2013 with Charge ID 10397211 was modified on 31 May 2025.
Charges
A charge with Others amounted to Rs. 0.30 Cr with Charge ID 101051744 was registered on 31 Jan 2025.
Charges
A charge with Others amounted to Rs. 0.30 Cr with Charge ID 101051749 was registered on 31 Jan 2025.
Charges
A charge registered on 25 Oct 2021 via Charge ID 100500881 with Others was fully satisfied on 08 Jan 2025.
Charges
A charge registered on 25 Oct 2021 via Charge ID 100500883 with Others was fully satisfied on 08 Jan 2025.
Ceased
Gopal Madhavbhai Daptari ceased to be Director.
124 earlier events are in the company report.
News
Gufic Biosciences: Gets Three Observations From USFDA At Pithampur Production Site
Frequently asked questions
Gufic Biosciences is an active public limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 23 July 1984 (42+ years old) and is registered under CIN L24100MH1984PLC033519. Listed on BSE: 509079 and NSE: GUFICBIO.
Gufic Biosciences reported revenue of ₹944.01 Cr for FY 2025-26 (up 15.1% YoY) based on consolidated financials.
Gufic Biosciences has 6 current directors:
- Jayesh Pannalal Choksi - Managing Director
- Pranav Jayesh Choksi - Whole-Time Director
- Pankaj Jayakumar Gandhi - Whole-Time Director
- Anu Sanjiv Aurora - Director
- Akshya Kumar Mahapatra - Director
- Kamal Kishore Seth - Director
The latest financial statements of Gufic Biosciences on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 29 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Gufic Biosciences is 27AAACC3419N1ZK, registered in Maharashtra. The company has 22 GST registrations in all, of which 20 are active and 2 are cancelled or inactive. Other active GSTINs include 27AAACC3419N2ZJ (Maharashtra), 07AAACC3419N1ZM (Delhi), 08AAACC3419N1ZK (Rajasthan).
The CIN (Corporate Identification Number) of Gufic Biosciences is L24100MH1984PLC033519. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Gufic Biosciences is a listed company as per MCA records. Its shares are listed on both BSE (code: 509079) and NSE (symbol: GUFICBIO).
Gufic Biosciences has 254 court cases on record: 204 filed by the company and 50 filed against it. 120 are pending. Most are in the district courts.
Gufic Biosciences was incorporated on 23 July 1984, making it 42+ years old. It is registered with the Registrar of Companies, Mumbai.
Gufic Biosciences has 18 deals on record (17 market trades, 1 funding round), with disclosed funding of ₹99.99 Cr; the latest was in November 2023.
The peers of Gufic Biosciences by revenue are Rubicon Research Limited, Fresenius Kabi Oncology Limited, Scott Edil Pharmacia Limited, Bliss GVS Pharma Limited, Apex Laboratories Private Limited and 3 more, all in the Pharma industry (Biosciences, Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Gopal Madhavbhai Daptari ceased to be Director on 24 Nov 2024. Akshya Kumar Mahapatra was appointed as Director on 14 Nov 2024. Shreyas Kantilal Patel ceased to be Director on 26 Sep 2024. Gufic Biosciences has 34 board changes on record in total.